Cost Containment To Define Pharmaceutical Forecast

BMI View: Long viewed as a refuge for leading drugmakers, government cost-cutting measures, including the promotion of generics and branded product price reductions, are expected to compress headline growth in Canada until 2016. While we anticipate healthcare reforms will place downward pressure on pharmaceutical margins, we highlight that Canada's strong regulatory environment and healthcare commitment bode well for the overall business environment.

To read the full article, please choose one of the following options: